Sun Pharma appoints Kirti Ganorkar as new MD
This move is part of a "structured and forward-looking succession planning process," the company stated, aimed at ensuring leadership continuity. The appointment is subject to shareholder approval at the upcoming Annual General Meeting.
Dilip Shanghvi, the current managing director, will step down from the role and transition to executive chairman of the board. In his new capacity, Shanghvi will dedicate his efforts to bolstering Sun Pharma's high-growth specialty portfolio and providing strategic oversight for the company's long-term vision.
Ganorkar, a Sun Pharma veteran who joined the company in 1996, has been instrumental in the company's growth. He has successfully spearheaded the India business since June 2019, significantly increasing market share. His extensive career at the pharmaceutical major includes key leadership positions across business development, marketing, and M&A. Notably, he played a pivotal role in driving the company's foray into the specialty drug market by securing rights for innovative products like Ilumya and overseeing its initial expansion into Japan and Europe.
Commenting on the appointment, Dilip Shanghvi said, "Kirti has consistently demonstrated effective leadership managing diverse roles at Sun. I have a firm belief in his ability to lead the company into its next phase of growth."
In another significant development, the company also announced changes within its North American operations. Abhay Gandhi, president & CEO for North America, is departing to pursue other interests. He will be succeeded by Richard "Rick" Ascroft, a seasoned biopharmaceutical executive boasting over three decades of experience. Ascroft previously served as senior vice president at Takeda Pharmaceuticals, heading the U.S. Plasma-Derived Therapies business unit. Aalok Shanghvi, Whole-time Director and Chief Operating Officer, will now also oversee the North America business, with Ascroft reporting directly to him.
Meanwhile, the company confirmed that the USFDA conducted a Good Manufacturing Practices (GMP) inspection of its Halol facility in Gujarat, India, from 2 June to 13 June 2025. Upon the conclusion of the inspection, the USFDA issued a Form-483 with 8 observations.
The companys consolidated net profit declined 19% to Rs 2,149.88 crore, despite an 8.5% increase in revenue from operations to Rs 12,815.58 crore in Q4 FY25 over Q4 FY24.
Sun Pharmaceutical Industries is the worlds leading specialty generics company with a presence in specialty, generics, and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as global emerging markets.
Shares of Sun Pharmaceutical Industries shed 0.60% to Rs 1,678.65 on the BSE.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Today
33 minutes ago
- India Today
ED seizes over Rs 127 crore shares in Alchemist Group money laundering scam
In a significant move in the ongoing money laundering probe against the Alchemist Group, the Directorate of Enforcement (ED) has seized shares worth Rs 127.33 crore of two hospitals — Alchemist Hospital and Ojas Hospital — located in Panchkula, hospitals are beneficially owned by Karan Deep Singh, son of former Rajya Sabha MP Kanwar Deep Singh. The seizure was carried out under the Prevention of Money Laundering Act (PMLA), 2002, as part of the ED's investigation into a large-scale financial scam involving fraudulent investment schemes and misappropriation of public case stems from an FIR initially lodged by Kolkata Police, which was later transferred to the Central Bureau of Investigation's (CBI) Anti-Corruption Branch in Lucknow. The companies under scrutiny include Alchemist Township Private Ltd and Alchemist Infra Realty Private Ltd and other group entities, with charges framed under IPC Sections 120-B (criminal conspiracy) and 420 (cheating). According to the ED, the Alchemist Group defrauded thousands of investors by collecting over Rs 1,848 crore through illegal Collective Investment Schemes (CIS), falsely promising high returns and property allotments. The collected funds were subsequently syphoned off and laundered via a network of group companies to conceal their have found that the laundered money was ultimately diverted to acquire shares and develop infrastructure in the two hospitals now seized. Sorus Agritech Private Ltd, a company controlled by Karan Deep Singh, holds 40.94 per cent in Alchemist Hospital and 37.24 per cent in Ojas latest seizure follows a series of actions in the case. Kanwar Deep Singh was arrested by the ED on January 12, 2021. The agency filed a prosecution complaint on March 2, 2021, and a supplementary complaint on July 19, 2024. So far, the ED has seized assets worth Rs 238.42 crore through five separate provisional financial probe agency has alleged that the entire operation was a textbook case of corporate fraud and laundering, wherein public funds were syphoned off under the guise of real estate investments, then disguised as legitimate through hospital infrastructure and equity investments.- EndsMust Watch
News18
34 minutes ago
- News18
Home buyers fraud: ED secures custody of 2 Ramprastha Group directors
Gurugram, Jul 23 (PTI) The Directorate of Enforcement (ED) on Wednesday secured two-day custody of Sandeep Yadav and Arvind Walia, promoters of Haryana-based realty company Ramprastha Group, in connection with a money laundering probe linked to an alleged Rs 1,100 crore fraud with homebuyers. The two were arrested on Monday after the Gurugram zonal office of the federal probe agency raided three premises in Delhi and Gurugram, including those of the directors, early morning on that day. Yadav and Walia are directors and majority shareholders in Ramprastha Promoters and Developers Pvt Ltd (RPDPL). They were taken into custody under the Prevention of Money Laundering Act (PMLA). The federal probe agency produced the two in the court of an additional session judge, following which the ED secured their custody. The agency conducted a survey against the group in September 2024. It is alleged that the RPDPL collected about Rs 1,100 crore from more than 2,000 homebuyers for various housing schemes like Project Edge, Project Skyz, Project Rise and Ramprastha City (plotted colony project) in various sectors of Gurugram during 2008-11. The possession of the flats or plots is yet to be given, even after 15-20 years, the sources said. Earlier this month, the agency attached colonies and plots spread across more than 1,900 acres and worth over Rs 681.54 crore of the group in Gurugram as part of this investigation. The money laundering case stems from multiple FIRs filed by the Economic Offences Wing (EOW) of the Delhi and Haryana Police based on complaints of numerous homebuyers against RPDPL and its promoters, like Yadav, Walia and Balwant Chaudhary for their 'failure" to deliver promised flats and plots within the promised timeframes, the ED had said in a statement. The company and its promoters 'diverted" the funds sources from buyers of these projects to its group companies as advances for the purchase of land parcels, instead of using them for completion of promised homes, it had said. PTI COR AMJ AMJ AMJ (This story has not been edited by News18 staff and is published from a syndicated news agency feed - PTI) view comments First Published: July 24, 2025, 00:45 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Time of India
39 minutes ago
- Time of India
Lodha Developers, Oberoi Realty shares fall up to 6% after block deals
NEW DELHI: Shares of Oberoi Realty and Lodha Developers saw large block deals worth USD 395 million (Rs 3,412 crore) on the stock exchanges, dragging the shares of two real estate majors down by up to 6 per cent on Wednesday. The deals, executed via open market transactions, involved the sale of institutional stakes in both companies. In case of Oberoi Realty, around 11 million or 1.1 crore equity shares -- equivalent to 3 per cent of the company's equity -- changed hands for USD 230 million (Rs 1,987.02 crore ) at a floor price of Rs 1,753.20 per share, reflecting a 4 per cent discount to the previous close, as per a term sheet accessed by PTI. Following the stake sale, shares of the Oberoi Realty fell 4.16 per cent to Rs 1,750.20 apiece on the NSE. Goldman Sachs acted as the sole placing agent for both transactions. Similarly, Mumbai-based Lodha Developers saw a block deal of around 9.8 million shares or 98 lakh shares, representing 1 per cent of its stake -- being sold for USD 165 million (Rs 1,424.97 crore). The floor price for the Lodha block deal was pegged at Rs 1,384.60 per share, also translating to a 4 per cent discount to the previous close on the bourse. Following the deal, the scrip of Lodha Developers declined by 6.64 per cent to Rs 1,346.50 per piece on the National Stock Exchange (NSE). "No confirmation was given on the identity of the seller or potential buyers, market participants expect the offloaded stakes to be picked up largely by domestic and foreign institutional investors, given the deal structure and volumes involved," sources said. Both block deals were executed as part of a clean-up trade by an existing stakeholder. The trades were conducted under Rule 144A and Regulation S guidelines, commonly used for placements to institutional and offshore investors, they added. Meanwhile, the selling pressure reflected in the NSE's Nifty realty index with all of its constituents trading in the red. The index fell 2.90 per cent to trade at 967.15, dragged down by losses in major stocks including Macrotech Developers (Lodha) and Oberoi Realty, which led the decline. Godrej Properties and Prestige Estates also witnessed significant losses, each shedding over 2 per cent in intraday trade. On Monday, Oberoi Realty reported a 28 per cent decline in its consolidated net profit to Rs 421.25 crore for the quarter ended in June on lower income. The net profit stood at Rs 584.51 crore in the year-ago period. Its total income fell to Rs 1,073.98 crore in the first quarter of this fiscal from Rs 1,441.95 crore in the corresponding period of the preceding year. On the operational front, the company has sold properties worth Rs 1,639 crore in the April-June quarter of 2025-26 fiscal.
